Comparative Pharmacology
Head-to-head clinical analysis: MINZOYA versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINZOYA versus NORTREL 1 35 21.
MINZOYA vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
Intravenous infusion of 300 mg over 30 minutes every 4 weeks.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Terminal elimination half-life of 20-30 hours; at steady state after 5-7 days, half-life reflects accumulation for once-daily dosing.
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Primarily hepatic metabolism with renal excretion of metabolites (50-60% as unchanged drug and conjugates); approximately 30-40% fecal elimination.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive